Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 26;19(1):1470320318759358. doi: 10.1177/1470320318759358

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 8. — TGF-β trap administration to partially reduced Ang-II-induced elevation of phosphorylated Smad2 levels at six hours. (a) Representative western blot images and semi-quantification using densitometry of pSmad2 and total Smad2/3 protein levels relative to actin at six hours. (b) Densitometry was used for semi-quantification of pSmad2 levels relative to total Smad2/3 protein levels. (c) Representative western blot images and semi-quantification using densitometry of pSmad2 and total Smad2/3 protein levels relative to actin at 24 hours. (d) Densitometry was used for semi-quantification of pSmad2 levels relative to total Smad2/3 protein levels.

Data are expressed as means ± SEM and normalized to actin.

n = 5–6.

*p < 0.05, compared to saline control.

Ang-II: Angiotensin II; PBS: phosphate-buffered saline; pSMAD2: phosphorylated Smad2; Ser: serine; Trap: TGF-β trap; TGF-β: transforming growth factor-β.